12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.

Date publication

avril 2018

Journal

Hepatology (Baltimore, Md.)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DI MARTINO Vincent , Dr HABERSETZER François

Tous les auteurs :
Houssel-Debry P, Coilly A, Fougerou-Leurent C, Jezequel C, Duvoux C, De Ledinghen V, Radenne S, Kamar N, Leroy V, Di Martino V, D'Alteroche L, Canva V, Conti F, Dumortier J, Montialoux H, Lebray P, Botta-Fridlund D, Tran A, Moreno C, Silvain C, Besch C, Perre P, Francoz C, Abergel A, Habersetzer F, Debette-Gratien M, Cagnot C, Diallo A, Chevaliez S, Rossignol E, Veislinger A, Duclos-Vallee JC, Pageaux GP,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29633389

Résumé

Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor-based regimen without RBV for 12 weeks after liver transplantation (LT).

Mots clés

Adult, Aged, Belgium, Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, France, Graft Survival, drug effects, Hepatitis C, Chronic, complications, Humans, Liver Cirrhosis, etiology, Liver Transplantation, adverse effects, Male, Middle Aged, Prognosis, Prospective Studies, Recurrence, Ribavirin, therapeutic use, Sofosbuvir, therapeutic use, Treatment Outcome, Viral Nonstructural Proteins, administration & dosage

Référence

Hepatology. 2018 Apr 10;: